Logo
For Sales: 888.816.4721 | Contact Us

WorldCare Clinical Expands Its Oncology Clinical Trial Services to Include Independent Assessments of Drug-Induced Cancers

June 25, 2015

Integrated "On Demand" Pathology and Oncology Diagnostic Services Will Type Any Malignancies

Boston, MA, June 25, 2015 – WorldCare Clinical (WCC), a leading CRO focused on maximizing the precision and accuracy of independent endpoint assessments in clinical trials, today announced its integrated pathology and cancer diagnostic service.

WCC’s cancer diagnostic service for clinical trials has been developed based on sponsor and regulatory concerns regarding the carcinogenic potential of investigational drugs. Through WCC’s strategic relationship with the Harvard Teaching Hospital System, WCC has established integrated teams of pathologists and oncologists from the Dana-Farber/Harvard Cancer Center who access a 21 CRF Part 11-compliant digital portal to provide independent verification of site-reported cancers. "This unique, full-service offering provides end-to-end logistics which includes slide preparation and staining, slide digitization, clinical data packaging, and clinical interpretation," stated Aaron Timm CEO of WCC. "As an on-demand offering, the service provides sponsors the flexibility of requesting assessments only when needed."

WCC’s "on-demand" service is a cost-efficient approach with minimal start-up cost and no monthly management fees. For more than 20 years WCC has managed endpoint assessment committees, including adjudication of both imaging and non-imaging endpoints. WCC offers multiple standing safety committees as well as efficacy adjudication for all clinical subspecialties. Similar to WCC’s imaging clinical trial services, its cancer diagnostic service for clinical trials employs only board-certified, subspecialty-trained practicing physicians.

About WorldCare Clinical

WorldCare Clinical is a global imaging CRO that employs scientific expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of Phase I – IV clinical trial data. The company has worked with thousands of sites in more than 60 countries. WCC’s robust technology platform processes over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WorldCare continues to maintain a strategic relationship with the Harvard Hospital System as well as other leading academic institutions.


For more information on WCC's services, please visit our website at wcclinical.com or contact:

Thomas O'Donnell

todonnell@wcclinical.com

(513) 924-5183